SPOTLIGHT: Mylan buying back stock


With Carl Icahn waiting in the wings with a buyout offer, Mylan Laboratories has announced a $1.25 billion stock buyback offer for 25 percent of its shares and a doubling of annual dividends. Story

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.